Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,323 people get DSCO articles and Market Currents by email alert.
Get email alerts on DSCO »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Discovery Labs Anticipating Active Year EndMike Havrilla • Fri, Sep 19, 2008 -
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Small Biotech Companies: Please Tread CarefullyDoolan Wesley • Tue, Jun 26, 2012
-
-
-
-
-
-
-
-
-
-
-
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 10, 2013)
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Feb 13, 2013)
-
GlobeNewswire (Jan 17, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Jan 3, 2013)
-
PR Newswire (Nov 28, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Oct 24, 2012)
DSCO vs. ETF Alternatives
Company Description
Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a Delaware corporation, with our principal offices located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania. We were incorporated as a Delaware corporation in 1992. Our telephone number is 215-488-9300 and our... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 7:58 AM Discovery Labs (DSCO): Q1 EPS of -$0.29 misses by $0.03. Revenue of $72K beats by $62K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, April 15, 5:42 PM Discovery Labs (DSCO) files a registration with the SEC to sell up to 2.34M shares of on behalf of selling shareholders. The company will not receive proceeds from the secondary offering. Comment! [Healthcare]
- Monday, April 15, 1:35 PM Discovery Labs (DSCO -17%) gets slammed today after coming off an early morning halt on news the FDA had requested clarification and provided recommendations regarding the recently updated product specifications for Surfaxin, which is used to treat respiratory distress syndrome. The company says it plans to provide a response within two months, and if the FDA gives the green light, it expects to proceed with commercialization in Q413. 1 Comment [Healthcare, On the Move]
-
Monday, April 15, 12:50 PM
Midday top 10 gainers: MKTAY +143%. CNIT +21%. GENE +21%. THRX +18%. MCOX +17%. SGRP +14%. S +13%. STXS +10%. ACOR +9%. LIFE +8%.
Midday top 10 losers: UNTK -48%. GSS -19%. ASM -18%. DSCO -17%. HXM -16%. XPL -16%. NGD -16%. TGD -15%. BAA -14%. PZG -14%. Comment! [On the Move] -
Monday, April 15, 9:15 AM
Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move] - Monday, April 15, 7:59 AM Discovery Labs (DSCO) announces it received FDA recommendations and a request for clarification on Surfaxin. The company plans to provide a response to the agency within two months. DSCO halted. Comment! [Healthcare]
- Monday, April 15, 7:52 AM Shares of Discovery Labs (DSCO) are halted with news pending. Comment! [Healthcare]
- Sunday, April 14, 10:48 PM The rest of the top 25 June deletions from the Russell 2000 expected by Credit Suisse: QUIK, IVAC, TINY, DSCO, RLOG, RMTI, AGEN, MSPD, DRL, AXTI, ELON, GYRO, CDZI, IQNT, BSCT, UAMY, MTSN, AUMN, URZ, INOD. ''IQNT is one of the more well-owned deletes among small cap funds," says CS. Comment! [Quick Ideas]
- Wednesday, March 13, 7:49 AM Discovery Labs (DSCO): Q4 EPS of -$0.16 beats by $0.12. Revenue of $195K beats by $135K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 14, 3:34 PM Discovery Lab (DSCO +23%) soars after inking a deal with Deerfield Management to provide up to $30M in debt financing for the biotech company. The new funds will be used to commercialize Surfaxin, which was approved last March by the FDA to treat respiratory distress syndrome in premature infants. Seeking Alpha contributor Larry Smith says the favorable terms of the financing provide a strong catalyst to buy the stock. Comment! [Healthcare, On the Move]
-
Thursday, February 14, 12:46 PM
Midday top 10 gainers: STZ +37%. ART +32%. ANGI +24%. EMITF +21%. HNZ +20%. FFEX +20%. MEIP +18%. VCLK +17%. SPWR +17%. DSCO +16%.
Midday top 10 losers: TBAC -40%. NSPH -31%. END -31%. CTL -22%. WTW -17%. STMP -16%. STRA -11%. ULTA -11%. TCX -11%. ITRI -10%. Comment! [On the Move] - Friday, January 4, 11:34 AM Discovery Labs (DSCO -2.1%) dips after it says W. Thomas Amick has resigned as Chairman and CEO. In his stead, the board has appointed John G. Cooper as President and CEO and has been elected to the Company's board of directors, while John R. Leone is appointed Chairman of the board. 1 Comment [On the Move]
- Tuesday, December 4, 2012, 2:11 PM Discovery Laboratories (DSCO +4.9%) moves up today after releasing data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with Surfaxin may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia. Comment! [Healthcare, On the Move]
- Wednesday, November 28, 2012, 11:02 AM Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products, Surfaxin and Afectair, at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Surfaxin is the first FDA-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome in premature high risk infants, while in February 2012 Afectair, a ventilator circuit that simplifies the delivery of inhaled therapies to critical care patients requiring ventilator support, was recently cleared with the FDA for marketing in the U.S. Comment! [Healthcare]
- Wednesday, October 24, 2012, 2:24 PM Discovery Lab (DSCO -12.5%) tanks after saying the commercial launch of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will likely be delayed until Q2 of 2013. Expectations had been for it to be released by the end of the year. 3 Comments [Healthcare, On the Move]
- Wednesday, October 24, 2012, 12:45 PM Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%. Comment! [On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.